William James
Partner
Washington, D.C.
William James
Partner
Washington, D.C.
Contact details
Bill is a patent litigator in the Intellectual Property practice. He has more than 25 years of experience as a trial lawyer representing multinational companies in pharmaceutical and biotechnology patent litigation cases.
His most recent experience includes high stakes biotechnology-related district court, ITC litigation, and arbitration matters. He has significant trial experience for both innovators and generic companies in Hatch-Waxman litigations, including first-to-file cases and multi-defendant ANDA patent challenges. Bill helps companies coordinate on global patent and patent litigation issues.
Bill acts as Lead Counsel in IPR proceedings before the Patent Trial and Appeal Board (PTAB), and has participated in numerous appeals, including appeals before the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court.
He advises pharmaceutical and biotechnology companies, including animal health companies on freedom-to-operate, due diligence, licensing, and prosecution matters. Bill’s experience coordinating worldwide patent and patent litigation matters includes assisting clients with issues in the U.K., the Netherlands, France, Russia, Israel, Australia, Canada, and Mexico, and in the European Patent Office.
Bill is a member of the American Bar Association, the New York Intellectual Property Law Association and the American Intellectual Property Law Association.
Bill has served various firm-management roles.
Qualifications
Professional
Registered Foreign Lawyer, England and Wales, 2024
Admitted to the Bar of the State of New York, 1997
Admitted to the Bar of the District of Columbia, 2007
U.S. Patent and Trademark Office (USPTO), 2003
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
U.S. Court of Appeals for the Federal Circuit
United States Supreme Court
Academic
JD, New York University, School of Law, 1996
D.V.M., Oklahoma State University, 1989
Experience highlights
Novartis in ITC and District Court patent and antitrust litigation adverse to Regeneron on the Eylea® Pre-filled Syringe. *Previous firm experience
Aegerion Pharmaceuticals and the University of Pennsylvania as lead counsel in defeating IPRs filed by the Coalition for Affordable Drugs challenging patents covering the use of the Juxtapid® (lomitapide) product. *Previous firm experience
Teva in patent litigation protecting Teva’s largest brand product, Copaxone®, from generic competition. *Previous firm experience
Intervet and Schering Animal Health in patent litigation against Merial relating to the Circumvent® vaccine product.
Related articles
News: 21 July 2023
A&O’s patent practices and lawyers secure top rankings in leading intellectual property platform
Intellectual Asset Management (IAM) Patent, the world’s leading patent business media platform, has released its annual rankings guide, listing 16 practices and 32 Allen & Overy lawyers. The platform…
Qualifications
Professional
Registered Foreign Lawyer, England and Wales, 2024
Admitted to the Bar of the State of New York, 1997
Admitted to the Bar of the District of Columbia, 2007
U.S. Patent and Trademark Office (USPTO), 2003
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
U.S. Court of Appeals for the Federal Circuit
United States Supreme Court
Academic
JD, New York University, School of Law, 1996
D.V.M., Oklahoma State University, 1989
Pro Bono
- Bill has represented U.S. military veterans in appeals before the Board of Veterans’ Appeals and the U.S. Court of Appeals for Veterans Claims.
- In addition, Bill has assisted green card holders seeking U.S. citizenship.
Awards & accolades
Litigation Star, Intellectual Property, Washington, D.C.
Benchmark Litigation, 2021
IAM Patent 1000
2022
Recognition
Bill has developed a reputation as one of the pre-eminent patent litigators in the country and is the person we go to on our most important and high-stakes cases.
IAM Patent 1000
Published Work
- Co-Author, “The Name Game: The Debate Over Naming Follow-on Biologics,” Genetic Engineering & Biotechnology News (July 2, 2014)
- Co-Author, Chapter on U.S. Patent Law, Getting the Deal Through – Patents in 37 Jurisdictions Worldwide – 2014 (May 16, 2014)
- Contributor, Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020, 2021-2022 editions
